Canada explains GMP evidence requirements for drug applications
This article was originally published in SRA
Executive Summary
Health Canada has issued a notice summarising the evidence that companies must submit in their drug applications to show compliance with good manufacturing practice requirements1. This move builds on the regulator’s recent efforts to strengthen its GMP framework with a view to aligning it with international standards2.